参考文献
[1] Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study[J]. Lancet, 2006,368(9540):1005-1011. DOI: 10.1016/S0140-6736(06)69208-8.
[2] d′Arcy JL, Coffey S, Loudon MA, et al. Large-scale community echocardiographic screening reveals a major burden of undiagnosed valvular heart disease in older people: the OxVALVE Population Cohort Study[J]. Eur Heart J, 2016,37(47):3515-3522. DOI: 10.1093/eurheartj/ehw229.
[3] Dziadzko V, Dziadzko M, Medina-Inojosa JR, et al. Causes and mechanisms of isolated mitral regurgitation in the community: clinical context and outcome[J]. Eur Heart J, 2019,40(27):2194-2202. DOI: 10.1093/eurheartj/ehz314.
[4] Wu AH, Aaronson KD, Bolling SF, et al. Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction[J]. J Am Coll Cardiol, 2005,45(3):381-387. DOI: 10.1016/j.jacc.2004.09.073.
[5] Michler RE, Smith PK, Parides MK, et al. Two-year outcomes of surgical treatment of moderate ischemic mitral regurgitation[J]. N Engl J Med, 2016,374(20):1932-1941. DOI: 10.1056/NEJMoa1602003.
[6] Goldstein D, Moskowitz AJ, Gelijns AC, et al. Two-year outcomes of surgical treatment of severe ischemic mitral regurgitation[J]. N Engl J Med, 2016,374(4):344-353. DOI: 10.1056/NEJMoa1512913.
[7] Smith PK, Puskas JD, Ascheim DD, et al. Surgical treatment of moderate ischemic mitral regurgitation[J]. N Engl J Med,2014,371(23):2178-2188. DOI: 10.1056/NEJMoa1410490.
[8] Obadia JF, Messika-Zeitoun D, Leurent G, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation[J]. N Engl J Med, 2018,379(24):2297-2306. DOI: 10.1056/NEJMoa1805374.
[9] Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter mitral-valve repair in patients with heart failure[J]. N Engl J Med, 2018,379(24):2307-2318. DOI: 10.1056/NEJMoa1806640.
[10] Sannino A, Smith RL 2nd, Schiattarella GG, et al. Survival and cardiovascular outcomes of patients with secondary mitral regurgitation: a systematic review and meta-analysis[J]. JAMA Cardiol, 2017,2(10):1130-1139. DOI: 10.1001/jamacardio.2017.2976.
[11] Ailawadi G, Lim DS, Mack MJ, et al. One-year outcomes after MitraClip for functional mitral regurgitation[J]. Circulation, 2019,139(1):37-47. DOI: 10.1161/CIRCULATIONAHA.117.031733.
[12] Iung B, Armoiry X, Vahanian A, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation: outcomes at 2 years[J]. Eur J Heart Fail, 2019,21(12):1619-1627. DOI: 10.1002/ejhf.1616.
[13] Fernández-Ruiz I. Still no benefit of MitraClip in MITRA-FR[J]. Nat Rev Cardiol, 2019,16(11):649. DOI: 10.1038/s41569-019-0280-4.
[14] Enriquez-Sarano M, Michelena HI, Grigioni F. Treatment of functional mitral regurgitation[J]. Circulation, 2019,139(20):2289-2291. DOI: 10.1161/CIRCULATIONAHA.118.038207.
[15] Carabello BA. MitraClip and tertiary mitral regurgitation-mitral regurgitation gets curiouser and curiouser[J]. JAMA Cardiol, 2019,4(4):307-308. DOI: 10.1001/jamacardio.2019.0195.
[16] Senni M, Adamo M, Metra M, et al. Treatment of functional mitral regurgitation in chronic heart failure: can we get a ‘proof of concept’ from the MITRA-FR and COAPT trials?[J]. Eur J Heart Fail, 2019,21(7):852-861. DOI: 10.1002/ejhf.1491.
[17] Delgado V, Ajmone Marsan N, Bax JJ. Characterizing mitral regurgitation in a contemporary population: prognostic implications[J]. Eur Heart J, 2019,40(27):2203-2205. DOI: 10.1093/eurheartj/ehz432.
[18] Grayburn PA, Sannino A, Packer M. Proportionate and disproportionate functional mitral regurgitation: a new conceptual framework that reconciles the results of the MITRA-FR and COAPT trials[J]. JACC Cardiovasc Imaging, 2019,12(2):353-362. DOI: 10.1016/j.jcmg.2018.11.006.
[19] Adamo M, Godino C, Giannini C, et al. Left ventricular reverse remodelling predicts long-term outcomes in patients with functional mitral regurgitation undergoing MitraClip therapy: results from a multicentre registry[J]. Eur J Heart Fail, 2019,21(2):196-204. DOI: 10.1002/ejhf.1343.
[20] Packer M, Grayburn PA. Contrasting effects of pharmacological, procedural, and surgical interventions on proportionate and disproportionate functional mitral regurgitation in chronic heart failure[J]. Circulation, 2019,140(9):779-789. DOI: 10.1161/CIRCULATIONAHA.119.039612.
[21] Kang DH, Park SJ, Shin SH, et al. Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation[J]. Circulation, 2019,139(11):1354-1365. DOI: 10.1161/CIRCULATIONAHA.118.037077.
[22] Topilsky Y, Oh JK, Atchison FW, et al. Echocardiographic findings in stable outpatients with properly functioning HeartMateⅡ left ventricular assist devices[J]. J Am Soc Echocardiogr, 2011,24(2):157-169. DOI: 10.1016/j.echo.2010.12.022.
[23] Packer M, Grayburn PA. Neurohormonal and transcatheter repair strategies for proportionate and disproportionate functional mitral regurgitation in heart failure[J]. JACC Heart Fail, 2019,7(6):518-521. DOI: 10.1016/j.jchf.2019.03.016.
[24] Sannino A, Sudhakaran S, Milligan G, et al. Effectiveness of medical therapy for functional mitral regurgitation in heart failure with reduced ejection fraction[J]. J Am Coll Cardiol, 2020,76(7):883-884. DOI: 10.1016/j.jacc.2020.05.079.
[25] Frea S, Pidello Md S, Boretto Md P, et al. Disproportionate functional mitral regurgitation predicts a favourable response after MitraClip implant in patients with advanced heart failure. Real-world evidence of a new conceptual framework[J]. Int J Cardiol, 2021,323:208-212. DOI: 10.1016/j.ijcard.2020.08.026.
[26] Tamargo M, Obokata M, Reddy Y, et al. Functional mitral regurgitation and left atrial myopathy in heart failure with preserved ejection fraction[J]. Eur J Heart Fail, 2020,22(3):489-498. DOI: 10.1002/ejhf.1699.
[27] Raghunathan D, Garcia-Sayan E, Schechter M, et al. First-in-human report of MitraClip G4 implantation for torrential tricuspid regurgitation and severe secondary mitral regurgitation[J]. JACC Cardiovasc Interv, 2020,13(13):1599-1602. DOI: 10.1016/j.jcin.2020.02.034.
[28] Kriechbaum SD, Boeder NF, Gaede L, et al. Mitral valve leaflet repair with the new PASCAL system: early real-world data from a German multicentre experience[J]. Clin Res Cardiol, 2020,109(5):549-559. DOI: 10.1007/s00392-019-01538-3.
[29] Pan W, Zhou D, Wu Y, et al. First-in-human results of a novel user-friendly transcatheter edge-to-edge mitral valve repair device[J]. JACC Cardiovasc Interv, 2019,12(23):2441-2443. DOI: 10.1016/j.jcin.2019.05.043.